* Lumos Pharma Inc LUMO.OQ LUMO.O is expected to show a
fall
in quarterly revenue when it reports results on May 1
(estimated) for the period ending March 31 2024
* The Austin Texas-based company is expected to report a
56.2% decrease in revenue to $302.6 thousand from $691 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Lumos Pharma Inc is for
a loss
of $1.18 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lumos
Pharma Inc
is $23.00, above its last closing price of $2.77.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.25 -1.15 -1.17 Missed -1.7
Sep. 30 2023 -1.14 -1.15 -1.04 Beat 9.4
Jun. 30 2023 -1.09 -1.10 -1.09 Beat 0.6
Mar. 31 2023 -1.11 -1.12 -0.89 Beat 20.8
Dec. -0.91 -0.93 -0.99 Missed -6.3
31 2022
Sep. 30 2022 -1.00 -1.01 -0.86 Beat 14.7
Jun. 30 2022 -0.98 -0.99 -0.94 Beat 4.6
Mar. 31 2022 -0.89 -0.89 -0.92 Missed -3.1
This summary was machine generated April 29 at 20:18 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)